Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0445 Transporter Info
Gene Name SLC6A13
Transporter Name Sodium- and chloride-dependent GABA transporter 2
Gene ID
6540
UniProt ID
Q9NSD5
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Chemical Compound

  DT Modulation1

 Cisplatin co-treated with jinfukang results in decreased expression of SLC6A13 mRNA [2]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation1

 Benzo(a)pyrene results in decreased methylation of SLC6A13 5' UTR [16]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation2

 Benzo(a)pyrene results in decreased methylation of SLC6A13 promoter [16]

Regulation Mechanism

 Transcription Factor Info

  2-palmitoylglycerol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 2-palmitoylglycerol results in increased expression of SLC6A13 mRNA [12]

Regulation Mechanism

 Transcription Factor Info

  abrine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 abrine results in increased expression of SLC6A13 mRNA [13]

Regulation Mechanism

 Transcription Factor Info

  aristolochic acid I

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 aristolochic acid I results in increased expression of SLC6A13 mRNA [15]

Regulation Mechanism

 Transcription Factor Info

  epigallocatechin gallate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 potassium chromate(VI) co-treated with epigallocatechin gallate results in increased expression of SLC6A13 mRNA [17]

Regulation Mechanism

 Transcription Factor Info

  gamma-Aminobutyric Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 SLC6A13 results in increased export of gamma-Aminobutyric Acid [18]

Regulation Mechanism

 Transcription Factor Info

  Hydralazine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Hydralazine co-treated with Valproic Acid results in increased expression of SLC6A13 mRNA [19]

Regulation Mechanism

 Transcription Factor Info

  licochalcone B

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 licochalcone B results in increased expression of SLC6A13 mRNA [20]

Regulation Mechanism

 Transcription Factor Info

  methyleugenol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 methyleugenol results in decreased expression of SLC6A13 mRNA [9]

Regulation Mechanism

 Transcription Factor Info

  Methyl Methanesulfonate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Methyl Methanesulfonate results in increased expression of SLC6A13 mRNA [6]

Regulation Mechanism

 Transcription Factor Info

  N-Nitrosopyrrolidine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 N-Nitrosopyrrolidine results in decreased expression of SLC6A13 mRNA [9]

Regulation Mechanism

 Transcription Factor Info

  Okadaic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Okadaic Acid results in decreased expression of SLC6A13 mRNA [21]

Regulation Mechanism

 Transcription Factor Info

  PCI 5002

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 PCI 5002 co-treated with Zinc results in increased expression of SLC6A13 mRNA [22]

Regulation Mechanism

 Transcription Factor Info

  potassium chromate(VI)

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 potassium chromate(VI) co-treated with epigallocatechin gallate results in increased expression of SLC6A13 mRNA [17]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation2

 potassium chromate(VI) results in increased expression of SLC6A13 mRNA [17]

Regulation Mechanism

 Transcription Factor Info

  S-(1,2-dichlorovinyl)cysteine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides results in increased expression of SLC6A13 mRNA [24]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation2

 S-(1,2-dichlorovinyl)cysteine results in increased expression of SLC6A13 mRNA [24]

Regulation Mechanism

 Transcription Factor Info

  Silver

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Silver results in increased expression of SLC6A13 mRNA [7]

Regulation Mechanism

 Transcription Factor Info

  sodium arsenite

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 sodium arsenite results in increased expression of SLC6A13 mRNA [25]

Regulation Mechanism

 Transcription Factor Info

  theaflavin-3,3'-digallate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 theaflavin-3,3'-digallate affects the expression of SLC6A13 mRNA [26]

Regulation Mechanism

 Transcription Factor Info

  Thiram

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Thiram results in increased expression of SLC6A13 mRNA [25]

Regulation Mechanism

 Transcription Factor Info

  Valproic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Hydralazine co-treated with Valproic Acid results in increased expression of SLC6A13 mRNA [19]

Regulation Mechanism

 Transcription Factor Info

  Zinc

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 PCI 5002 co-treated with Zinc results in increased expression of SLC6A13 mRNA [22]

Regulation Mechanism

 Transcription Factor Info

Approved Drug

  Arsenic

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Arsenic affects the expression of SLC6A13 [1]

  Cisplatin

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Cisplatin inhibits the expression of SLC6A13 [2]

  Testosterone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Testosterone increases the expression of SLC6A13 [4]

Drug Marketed but not Approved by US FDA

  Rotenone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Rotenone inhibits the expression of SLC6A13 [3]

Drug in Phase 3 Trial

  Triclosan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Triclosan increases the expression of SLC6A13 [8]

Investigative Drug

  SNAP-5114

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 SNAP-5114 inhibits the activity of SLC6A13 [11]

Natural Product

  Methyleugenol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Methyleugenol inhibits the expression of SLC6A13 [9]

  Tobacco Smoke Pollution

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Tobacco Smoke Pollution increases the expression of SLC6A13 [10]

  Resveratrol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Plant Extracts co-treated with Resveratrol results in decreased expression of SLC6A13 mRNA [23]

Regulation Mechanism

 Transcription Factor Info

Traditional Medicine

  Jinfukang

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Jinfukang inhibits the expression of SLC6A13 [2]

Mycotoxins

  Aflatoxin B1

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Aflatoxin B1 inhibits the expression of SLC6A13 [5]

  DT Modulation2

 Aflatoxin B1 results in increased methylation of SLC6A13 intron [14]

Regulation Mechanism

 Transcription Factor Info

Carcinogen

  Ethyl Methanesulfonate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Ethyl Methanesulfonate increases the expression of SLC6A13 [6]

  Benzo(a)pyrene

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Benzo(a)pyrene inhibits the expression of SLC6A13 [9]

Nanoparticle

  Silver nanoparticle

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Silver nanoparticle increases the expression of SLC6A13 [7]
References
1 Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. Environ Health Perspect. 2008 Apr;116(4):524-31.
2 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
3 Toxicity, recovery, and resilience in a 3D dopaminergic neuronal in vitro model exposed to rotenone. Arch Toxicol. 2018 Aug;92(8):2587-2606.
4 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384.
5 Identification of early target genes of aflatoxin B1 in human hepatocytes, inter-individual variability and comparison with other genotoxic compounds. Toxicol Appl Pharmacol. 2012 Jan 15;258(2):176-87.
6 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
7 Toxicogenomic responses of human liver HepG2 cells to silver nanoparticles. J Appl Toxicol. 2015 Oct;35(10):1160-8.
8 Transcriptome and DNA Methylome Dynamics during Triclosan-Induced Cardiomyocyte Differentiation Toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
9 Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297.
10 Integration of transcriptome analysis with pathophysiological endpoints to evaluate cigarette smoke toxicity in an in vitro human airway tissue model. Arch Toxicol. 2021 May;95(5):1739-1761.
11 Synaptic and extrasynaptic GABA transporters as targets for anti-epileptic drugs. J Neurochem. 2009 May;109 Suppl 1:139-44.
12 Direct effect of 2-palmitoyl glycerol on promotion of gamma aminobutyric acid synthesis in normal human fetal-derived astrocytes. FEBS Open Bio. 2023;13(7):1320-1332.
13 Integration of transcriptomics, proteomics and metabolomics data to reveal the biological mechanisms of abrin injury in human lung epithelial cells. Toxicol Lett. 2019;312:1-10.
14 Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018;121:214-223.
15 Integration of transcriptomic, proteomic and metabolomic data to reveal the biological mechanisms of AAI injury in renal epithelial cells. Toxicol In Vitro. 2021;70:105054.
16 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017;8(1):1369-1391.
17 Epigallocatechin-3-gallate (EGCG) protects against chromate-induced toxicity in vitro. Toxicol Appl Pharmacol. 2012 Jan 15;258(2):166-75.
18 Mechanisms of GABA release from human astrocytes. Glia. 2011;59(11):1600-11.
19 A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One. 2006;1(1):e98.
20 Integrated miRNA and mRNA omics reveal the anti-cancerous mechanism of Licochalcone B on Human Hepatoma Cell HepG2. Food Chem Toxicol. 2021;150:112096.
21 A multi-omics approach to elucidate okadaic acid-induced changes in human HepaRG hepatocarcinoma cells. Arch Toxicol. 2024;98(9):2919-2935.
22 Synthesis and anticancer properties of water-soluble zinc ionophores. Cancer Res. 2008 Jul 1;68(13):5318-25.
23 One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res. 2013;72:69-82.
24 The trichloroethylene metabolite S-(1,2-dichlorovinyl)-l-cysteine inhibits lipopolysaccharide-induced inflammation transcriptomic pathways and cytokine secretion in a macrophage cell model. Toxicol In Vitro. 2022;84:105429.
25 High-Throughput Transcriptomics of Nontumorigenic Breast Cells Exposed to Environmentally Relevant Chemicals. Environ Health Perspect. 2024;132(4):47002.
26 Theaflavin 3, 3'-Digallate Delays Ovarian Aging by Improving Oocyte Quality and Regulating Granulosa Cell Function. Oxid Med Cell Longev. 2021;2021:7064179.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.